"Medical Speed Reading Society" to open up the pharmaceutical market hong Kong Stock Exchange four provinces jointly purchase medical supplies

medical supplies with volume procurement! Yugui Yunyu four provincial alliance began to act
21, Chongqing Municipal Health Insurance Bureau, Guizhou Provincial Health Insurance Bureau, Yunnan Provincial Health Insurance Bureau, Henan Provincial Health Insurance Bureau jointly organized the procurement of medical supplies centralized band, four provinces (cities) Health Insurance Bureau decided to carry out cross-regional alliance centralized band procurement work"Announcement" shows that the procurement of varieties for the matchmaker, patch, film 3 types of medical suppliesThe public medical institutions (including military hospitals) in the areas of the alliance procurement area (including the army hospital) as the central procurement subject, according to the number of enterprises shortlisted for products, using a variety of procurement models such as bidding, bargaining, negotiation and so on(Chongqing Municipal Health Insurance Bureau, etc.)May 23, the State Drug Administration decided to dokuest sodium dancepher capsule specifications "adverse reactions", "precautions" and other items to be revisedAmong them, the indications were modified to "constipation of life-threatening patients who are not effective in other treatments." " (The State Drug Administration)the State Drug Administration organized the semiconductor laser treatment machine, glucose testing kit, soft contact mirror and other products of 6 varieties of quality supervision and sampling, a total of 24 batches (Taiwan) products do not meet the standard severance(State Drug Administration)22, innovative pharmaceutical enterprises to develop pharmaceutical industry officially listed on the Hong Kong Stock ExchangeThe IPO, which will be the sole sponsor of Huatai International, will issue 92.3475 million shares, with a single share priced at HK$20.15 and raising HK$1,854 million(Pharmaceutical Rubik's Cube)HotSpot Therapeutics announced the completion of a $65 million Round B financing to continue the clinical development of its candidate drugs, including protein kinase C (PKC-theta) antagonists for type 2 auxiliary T-cells and regulatory T-cell-driven autoimmune diseases, and S6 kinase resistance for rare metabolic diseasesThis round of financing will also accelerate the development of proven transcription factors and E3-linked enzymes, including CBL-B, to treat rare diseases and cancersKadmon Corporation announced that its oral selective ROCK2 inhibition of belumosudil, in the treatment of chronic transplant anti-host disease patients in the key trial ROCKstar, reached the total mitigation rate of the main research endpointKadmon is submitting a new drug application to the FDA under the Real-Time Oncology Review Pilot Project, which is expected to be completed in the fourth quarter of this year(Pharmacine Cond)
Gilead Sciences and Galapagos, Inc., jointly announced that its joint development of JAK1 selective inhibitor filgotinib, in the treatment of severe active ulcerative colitis in adult patients in the 2b/3 clinical trial SELECTION, obtained positive top-line results A recent eight-year, three-phase clinical study confirmed that "Patozumab and trastuzumab (trastuzumab) and dositarace" are used in a three-drug joint treatment for HER2-positive breast cancer, which can significantly improve the quality of life and survival time of patients This is another significant clinical result of drug co-use that has benefited patients more, and the results were recently published in the internationalauthoritative journal Lancet Oncology (CPhI PharmaceuticalS.) Sunovion Pharma, a U.S subsidiary of Sumitomo Pharmaceuticals, has announced that the U.S FDA has approved kynmobi (apomorphine HCl, apomorphine hydrochloride morphine) sub-tongue membrane agent for acute intermittent treatment for fluctuations in motor symptoms in people with Parkinson's disease Kynmobi dissolves under the tongue to help PD patients improve their OFF symptoms as needed (Bio Valley) Roche recently announced that Health Canada has approved a new adaptation of the anti-cancer drug Rozlytrek to treat patients with ROS1 fusion-positive, localized advanced or metastatic non-small cell lung cancer who have not previously received cintotrini Previously, Rozlytrek has been approved by Canada to treat adult patients with neurotrophic tyrosine receptor kinase gene fusion positive, no known acquired drug-resistant mutations, no satisfactory treatment options, non-reformeral late-stage or metastatic extracranial metastatic tumors, including brain metastases (Bio Valley) Astellas recently announced that the European Medicines Agency has accepted the marketing authorization application of Evrenzo (roxadustat, Rosasta), the drug for adult patients to treat chronic kidney disease-related anemia, including non-dialysis-dependent patients and dialysis-dependent patients (Bio Valley) Karyopharm Therapeutics recently announced that it has submitted a new drug application to the FDA seeking approval of Xpovio as a new treatment for patients with multiple myeloma who have previously received at least one treatment The company also plans to submit Xpovio's marketing license application for the same indications to the European Medicines Agency later this year (Bio Valley) 20, Haussen Pharmaceuticals submitted a four-category generic drug cider sulccoptic vaffirant film listing application according to the priority review scope (i) 4 patents expired one year before the pharmaceutical production application is to be included in the priority review process The study found that the new coronavirus is different in suppressing the cellular immune response, influenza virus and SARS virus will inhibit interferon and chemokine factors at the same time, while the new coronavirus inhibits interferon signaling pathways, but does not inhibit the tendency factor-mediated signaling pathway (Pharmaceutical Mingkant)